Teva gets generic Omnicef OK, starts shipping
The US Food and Drug Administration has granted approval for Israeli firm Teva Pharmaceutical Industries' Abbreviated New Drug Applications to market its generic versions of Abbott Laboratories' antibiotic Omnicef (cefdinir) capsules, 300mg, and for oral suspension, 125mg/5ml and 250mg/5ml. Teva says it has commenced shipment of these products.
Omnicef capsules and Omnicef suspension had annual sales of around $325.0 million and $533.0 million, respectively, in the USA based on IMS Health data.
Teva is currently in patent litigation concerning this product in the US District Court for the Northern District of Illinois, in a suit was brought against the firm in March involving Abbott's US Patent No 4,935,507. On May 3, the District Court denied Abbott's request for a preliminary injunction against Teva with respect to its cefdinir products. The Court found that Abbott had not proven a likelihood of success on its allegations of infringement of Teva's products, the Israeli firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze